CHINA BIOLOGIC PRODUCTS, INC. INDEPENDENT DIRECTOR AGREEMENTIndependent Director Agreement • March 23rd, 2012 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 23rd, 2012 Company Industry JurisdictionTHIS AGREEMENT (The “Agreement”) is made as of the 19th day of March 2012 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Yungang Lu (hereinafter referred to as the “Director”).
CHINA BIOLOGIC PRODUCTS, INC. INDEPENDENT DIRECTOR AGREEMENTIndependent Director Agreement • October 6th, 2011 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledOctober 6th, 2011 Company Industry JurisdictionTHIS AGREEMENT (The “Agreement”) is made as of the 6th day of October 2011 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and David (Xiaoying) Gao (hereinafter referred to as the “Director”).
CHINA BIOLOGIC PRODUCTS, INC. INDEPENDENT DIRECTOR AGREEMENTIndependent Director Agreement • March 3rd, 2011 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • New York
Contract Type FiledMarch 3rd, 2011 Company Industry JurisdictionTHIS AGREEMENT (The “Agreement”) is made as of the 27th day of February 2011 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Prof. Wenfang Liu (hereinafter referred to as the “Director”).
CHINA BIOLOGIC PRODUCTS, INC. INDEPENDENT DIRECTOR AGREEMENTIndependent Director Agreement • February 4th, 2010 • China Biologic Products, Inc. • Biological products, (no disgnostic substances) • California
Contract Type FiledFebruary 4th, 2010 Company Industry JurisdictionTHIS AGREEMENT (The “Agreement”) is made as of the 4th day of February 2010 and is by and between China Biologic Products, Inc., a Delaware corporation (hereinafter referred to as the “Company”), and Dr. Xiangmin Cui (hereinafter referred to as the “Director”).